
Podravka Group


Erste Group Investor Conference Stegersbach, October 2012





Content

Overview
Sales
Business results
Share performance




Disclaimer

This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of the Podravka Group. These forward-looking statements represent the Company's expectations or beliefs concerning future events and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.



Overview



Podravka is well known branded food company



One of the largest branded food companies in the region

- large brand portfolio with well known international and regional brands
- 6,543 employees

Podravka in Croatia

- one of the best known branded food producer
- the second pharmaceutical company per MS

Production facilities

- mostly in Croatia (food, beverages and drugs)
- Czech Republic, Poland (food), Bosnia&Herzegovina (drugs)

Coumpound of two Strategic Business Areas (SBA)

STRATEGIC BUSINESS AREA **Pharmaceuticals** Food and beverages **BUSINESS PROGRAM** Dishes&Food RX OTC **Pharmacies** Food Meat **Beverages** seasonings Alimentary tract & metabolism •OTC drugs Baby food Universal Canned meat •Blood & blood forming organs Mineral water Food supplement Cream spreads & seasonings Cardiovascular system Fresh meat Spring water snack Herbal products Special Dermatologicals Frozen shaped •lce tea seasonings Sweets & cereals meat •Genito urinary system & sex hormones Juice Meal makers •Fishery products & Sauces •Syrup olives ' Podravka •General antiinfectives for systemic use Sausage products Instant beverage Fruits & vegetables dishes •Musculo - skeletal system Paté •Tea •Mill & bakery Nervous system products Antiparasitic products Tomato products & side dishes Respiratory system Malignant disease and immunomodulators





SBA Food and Beverages

- Podravka offers a wide range of high quality, safe and practical products, from the best raw materials
- Combination of international, regional and local brands

INTERNATIONAL





SOUPS, BOUILLONS, SAUCES, HALF-READY DISHES, PROSESSED FRUIT AND VEGETABLE PRODUCTS, CONDIMENTS, TEA, MEAT PRODUCTS, BAKERY PRODUCTS, FROZEN PRODUCTS

REGIONAL







OTHER BRANDS























SBA Pharmaceuticals

- Belupo develops, improves and produces prescription and non-prescription drugs
- strong position in Croatia where it is the leading Croatian company in the group of medicine having effect on the cardiovascular system, nervous system and on the skin and leader in sales of OTC painkiller drugs
- increasing international sales

































Overview of business characteristic in 1H 2012

Podravka Group business results

- Sales: The total sales of the Podravka Group in the first six months of 2012 amounted to HRK 1,720.5 million and is almost at the identical level as in the same period of the year before. Sales of the Strategic Business Area (SBA) Food and Beverages totaled HRK 1,333.2 million, which is a sales drop of 3%, while the sales of the SBA Pharmaceuticals totaled HRK 387.3 million, representing a sales increase of 9%.
- **Profitability:** Realized EBITDA before one off items is HRK 1 million higher compared to the year 2011. EBITDA in 1H 2012 amounted HRK 160.8 million and EBITDA margin is 9.3% (1.2 p.p. lower than in the same period last year). Net profit is HRK 39.1 million (30% lower than in the same period last year).
- **Debt:** The positive trend of reducing debt is continued on the Group level. Net debt on 30 June 2012 amounted HRK 1,168.2 million which is HRK 70 million lower than at the end of 2011.
- **Investments:** In 1H 2012 it is realized HRK 47.1 million of investments and planned amount for 2012 is HRK 160 million.

Changes have been started...


Actions and activities performed

- Management Board has performed several changes in business organization and corporate governance, with the goal of improving processes and establishment more efficient decision making process. The most important changes include:
 - Establishment of Research and Development (R&D) as a sector, with strong focus on improvement of our existing
 products and developing new products, as a part of strategy for preserving and improving competitiveness in SBA
 Food & Beverages;
 - changes in organization of SBA Food & Beverages and personnel changes in some sectors in order to enhance business process;
 - changes and/or reduction of members in management and supervisory boards in subsidiaries Belupo and Danica,
 - as a part of strategy of focus on business efficiency and performance oriented remuneration, in early April, we conducted salary reduction for management in Croatia;
 - program of redundancy (288 employees left the company with September 1st);
 - start of the project which aims to establish an improved reporting system including improvement in SKU/Sales channel profitability reporting;
 - other activities with target of cost rationalization.

End of the year and strategy going forward


- the main objective of the Management Board and executives is to continue with the ongoing process of improvement and restructuring of business, especially in areas where below average profitability is observed and where deficiencies in the current business model is perceived.
- the Management Board is in the final stage of setting out the strategy and preparing detailed plan of initiatives and activities with the goal to implement the strategy the most efficiently.


Sales



Sales growth of SBA Pharmaceuticals compensate lower sales in SBA Food & Beverages


Sales structure by SBA for Jan – Jun 2012






Sales increase on foreign markets enables total sales growth, despite stagnation of domestic market

HRK mn



13

Sales revenues per markets



South East Europe (Albania, Bosnia and Herzegovina, Montenegro, Kosovo, Macedonia, Slovenia, Serbia)


Central Europe (Czech Republic, Hungary, Poland, Slovakia)

Western Europe, overseas countries and the Orient (Austria, Australia, Benelux, France, Canada, Germany, Great Britain, Scandinavia, Switzerland, Turkey, USA, other countries)

Eastern Europe (Bulgaria, Pribaltic, Romania, Russia, Ukraine, other countries of EE)



Business results



Podravka Group business results

HRK mn

PODRAVKA GROUP	REPORTED RESULTS		RESULTS CORRECTED FOR ONE-OFF ITEMS	change (reported results)	change (results corrected for one-off items)
	Jan-Jun 2012	Jan-Jun 2011	Jan-Jun Jan-Jun 2012 2011	Jan-Jun 2012 / Jan-Jun 2011	Jan-Jun 2012 / Jan-Jun 2011
Sales	1,720.5	1,724.2	1,720.5 1,724.2	0%	0%
Gross profit	658.3	668.7	658.3 668.7	-2%	-2%
EBITDA	160.8	181.1	168.2 167.3	-11%	1%
EBIT	84.2	102.2	91.6 88.4	-18%	4%
Net profit	39.1	55.6	46.5 46.7	-30%	0%
Profit margins %			; 		
Gross margin	38.3	38.8	38.3 38.8	-50bp	-50bp
EBITDA margin	9.3	10.5	9.8 9.7	-120bp	10bp
EBIT margin	4.9	5.9	5.3 5.1	-100bp	20bp
Net margin	2.3	3.2	2.7 2.7	-90bp	0bp
			į		

Business results of SBA Food & Beverages

HRK mn


SBA FOOD & BEVERAGES	REPORTED RESULTS		RESULTS change change CORRECTED (reported corrected for results) one-off items)
	Jan-Jun 2012	Jan-Jun 2011	Jan-Jun Jan-Jun Jan-Jun 2012 Jan-Jun 2012 2012 2011 / Jan-Jun 2011 / Jan-Jun 2011
Sales	1,333.2	1,369.9	1,333.2 1,369.9 - 3 % - 3 %
Gross profit	452.8	481.9	452.8 481.9 -6% -6%
EBITDA	88.4	97.0	95.6 106.8 - 9 % -10%
EBIT	35.0	40.3	42.2 50.1 -13% -16%
Net profit	8.5	15.9	15.7 25.7 -47% -39%
Profit margins %			
Gross margin	34.0	35.2	34.0 35.2 -120bp -120bp
EBITDA margin	6.6	7.1	7.2 7.8 -50bp -60bp
EBIT margin	2.6	2.9	3.2 3.7 -30bp -50bp
Net margin	0.6	1.2	1.2 1.9 -60bp -70bp


Business results of SBA Pharmaceuticals

HRK mn

Sales 387.3 354.3 387.3 354.3 9% 9% Gross profit 205.4 186.9 205.4 186.9 10% 10% EBITDA 72.4 84.1 72.6 60.5 -14% 20% EBIT 49.3 61.9 49.5 38.3 -20% 29% Net profit 30.6 39.7 30.8 21.0 -23% 47% Profit margins % Gross margin 53.0 52.8 53.0 52.8 20bp 20b EBITDA margin 18.7 23.7 18.7 17.1 -500bp 160b EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b	SBA PHARMACEUTICALS	REPORTED RESULTS		RESULTS CORRECTED FOR ONE-OFF ITEMS		change (reported results)	change (results corrected for one-off items)	
Gross profit 205.4 186.9 205.4 186.9 10% 10% EBITDA 72.4 84.1 72.6 60.5 -14% 20% EBIT 49.3 61.9 49.5 38.3 -20% 29% Net profit 30.6 39.7 30.8 21.0 -23% 47% Profit margins % Gross margin 53.0 52.8 53.0 52.8 20bp 20b EBITDA margin 18.7 23.7 18.7 17.1 -500bp 160b EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b				1		i i i i i i i i i i i i i i i i i i i	Jan-Jun 2012 / Jan-Jun 2011	
EBITDA 72.4 84.1 72.6 60.5 -14% 20% EBIT 49.3 61.9 49.5 38.3 -20% 29% Net profit 30.6 39.7 30.8 21.0 -23% 47% Profit margins % Gross margin 53.0 52.8 53.0 52.8 20bp 20b EBITDA margin 18.7 23.7 18.7 17.1 -500bp 160b EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b	Sales	387.3	354.3	387.3	354.3	9%	9%	
EBIT 49.3 61.9 49.5 38.3 -20% 29% Net profit 30.6 39.7 30.8 21.0 -23% 47% Profit margins %	Gross profit	205.4	186.9	205.4	186.9	10%	10%	
Net profit 30.6 39.7 30.8 21.0 -23% 479 Profit margins % Gross margin 53.0 52.8 53.0 52.8 20bp 20b EBITDA margin 18.7 23.7 18.7 17.1 -500bp 160b EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b	EBITDA	72.4	84.1	72.6	60.5	-14%	20%	
Profit margins % Gross margin 53.0 52.8 53.0 52.8 20bp 20b EBITDA margin 18.7 23.7 18.7 17.1 -500bp 160b EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b	EBIT	49.3	61.9	49.5	38.3	-20%	29%	
Gross margin 53.0 52.8 53.0 52.8 20bp 20b EBITDA margin 18.7 23.7 18.7 17.1 -500bp 160b EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b	Net profit	30.6	39.7	30.8	21.0	-23%	47%	
EBITDA margin 18.7 23.7 18.7 17.1 -500bp 160b EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b	Profit margins %				1			
EBIT margin 12.7 17.5 12.8 10.8 -480bp 200b	Gross margin	53.0	52.8	53.0	52.8	20bp	20bp	
	EBITDA margin	18.7	23.7	18.7	17.1	-500bp	160bp	
Not margin 7.0 44.2 0.0 5.0 220hn 240h	EBIT margin	12.7	17.5	12.8	10.8	-480bp	200bp	
1.9 11.2 0.0 5.9 -330bp 210b	Net margin	7.9	11.2	8.0	5.9	-330bp	210bp	

Indebtedness decrease in 1H 2012 for HRK 95 mn







decrease of debt for HRK 95 million (-7%)

Slowing down in increase of COGS, compared to the last two quarters of 2011

HRK 1,638.5 mn HRK 1,645.9 mn OPERATING COSTS




Share performance



Share price and volume movement

HRK '000 pieces



ZAGREB STOCK EXCHANGE PODR-R-A

BLOOMBERG PODRRA:CZ

REUTERS PODR.ZA

	Jan-Dec 2011	Jan-Aug 2012
Last price	231.00	215.50
Highest price	343.97	266.93
Lowest price	227.51	205.04
Turnover (HRK mn)	115.00	31.91
Mcap (HRK mn)	1,252.02	1,168.01

* data for September are up to 25/09/2012



Private domestic pension funds have increased share in shareholders structure

Shareholders structure as of 21 September 2012	
GAMA / CIPI	575,598 11%
■ GAMA / Repunlic of Croatia	535,567 10%
■ Erste plavi MPF	514,863 9%
■ AZ MPF	488,106 9%
■ PBZ Croatia osiguranje MPF	474,607 9%
■ Unicredit Bank Austria AG*	423,682 8%
■ Kapitalni fond d.d.	321,804 6%
■ Raiffeisen MPF	201,369 4%
■ PBZ d.d.*	101,027 2%
■ PBZ d.d./State street client	66,798 1%
account Treasury account	177.511 3 %
Other owners	1,539,071 28 %
Total	5,420,003

Shareholders structure as of 1 July 2011	
■ FIMA AMI Ltd.	576,880 11%
■ GAMA/CIPI	575,598 11%
■ GAMA/republic of Croatia	535,086 10%
■ Unicredit Bank Austria AG*	436,817 8%
■ PBZ Croatia osiguranje MPF	349,974 6%
■ Erste plavi MPF	325,163 6%
■ AZ MPF	324,291 6%
■ Kapitalni fond d.d.	321,804 6%
■ Raiffeisen MPF	176,512 3%
■ PBZ d.d.*	104,145 2 %
■ Treasury account	177,511 3 %
Other owners	1,516,222 28%
Total	5,420,003

GAMA (Government Asset Management Agency), CIPI (Croatian Institute for Pension Insurance), MPF (Mandatory Pension Fund) *omnibus custody account



Always with a heart PODERVER



Investor relations ir@podravka.hr